Literature DB >> 19459929

A proposed bailout for A-T patients?

Richard A Gatti, Susan Perlman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19459929      PMCID： PMC3242728          DOI： 10.1111/j.1468-1331.2009.02597.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  32 in total

Review 1.  Glutathione, oxidative stress and neurodegeneration.

Authors:  J B Schulz; J Lindenau; J Seyfried; J Dichgans
Journal:  Eur J Biochem       Date:  2000-08

2.  Cerebellar pathology in ataxia-telangiectasia: the significance of basket cells.

Authors:  R A Gatti; H V Vinters
Journal:  Kroc Found Ser       Date:  1985

3.  Ataxia-Telangiectasia: a multiparameter analysis of eight families.

Authors:  R A Gatti; M Bick; C F Tam; M A Medici; V A Oxelius; M Holland; A L Goldstein; E Boder
Journal:  Clin Immunol Immunopathol       Date:  1982-05

4.  IgG2 deficiency in ataxia-telangiectasia.

Authors:  V A Oxelius; A I Berkel; L A Hanson
Journal:  N Engl J Med       Date:  1982-03-04       Impact factor: 91.245

5.  Defective anti-polysaccharide antibody response in patients with ataxia-telangiectasia.

Authors:  Ozden Sanal; Filiz Ozbaş-Gerçeker; Leman Yel; Fügen Ersoy; Ilhan Tezcan; A Izzet Berkel; Ayşe Metin; Richard A Gatti
Journal:  Turk J Pediatr       Date:  2004 Jul-Sep       Impact factor: 0.552

6.  Ataxia telangiectasia mutated-dependent apoptosis after genotoxic stress in the developing nervous system is determined by cellular differentiation status.

Authors:  Y Lee; M J Chong; P J McKinnon
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

Review 7.  Ataxia-telangiectasia: diagnosis and treatment.

Authors:  Susan Perlman; Sara Becker-Catania; Richard A Gatti
Journal:  Semin Pediatr Neurol       Date:  2003-09       Impact factor: 1.636

Review 8.  Ataxia-telangiectasia, an evolving phenotype.

Authors:  Helen H Chun; Richard A Gatti
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

9.  Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals.

Authors:  C G Woods; A M Taylor
Journal:  Q J Med       Date:  1992-02

Review 10.  ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage.

Authors:  Ari Barzilai; Galit Rotman; Yosef Shiloh
Journal:  DNA Repair (Amst)       Date:  2002-01-22
View more
  8 in total

Review 1.  Radiological imaging in ataxia telangiectasia: a review.

Authors:  Ishani Sahama; Kate Sinclair; Kerstin Pannek; Martin Lavin; Stephen Rose
Journal:  Cerebellum       Date:  2014-08       Impact factor: 3.847

Review 2.  Ataxia.

Authors:  Umar Akbar; Tetsuo Ashizawa
Journal:  Neurol Clin       Date:  2015-02       Impact factor: 3.806

3.  Dexamethasone partially rescues ataxia telangiectasia-mutated (ATM) deficiency in ataxia telangiectasia by promoting a shortened protein variant retaining kinase activity.

Authors:  Michele Menotta; Sara Biagiotti; Marzia Bianchi; Luciana Chessa; Mauro Magnani
Journal:  J Biol Chem       Date:  2012-10-10       Impact factor: 5.157

4.  Forward subtractive libraries containing genes transactivated by dexamethasone in ataxia-telangiectasia lymphoblastoid cells.

Authors:  Sara Biagiotti; Michele Menotta; Elisa Giacomini; Lucia Radici; Marzia Bianchi; Cristina Bozzao; Luciana Chessa; Mauro Magnani
Journal:  Mol Cell Biochem       Date:  2014-03-14       Impact factor: 3.396

5.  Activation of NRF2 by dexamethasone in ataxia telangiectasia cells involves KEAP1 inhibition but not the inhibition of p38.

Authors:  Sara Biagiotti; Marzia Bianchi; Luigia Rossi; Luciana Chessa; Mauro Magnani
Journal:  PLoS One       Date:  2019-05-20       Impact factor: 3.240

6.  Ataxia-Telangiectasia Presenting as Cerebral Palsy and Recurrent Wheezing: A Case Report.

Authors:  Marta Navratil; Vlasta Đuranović; Boro Nogalo; Alen Švigir; Iva Dumbović Dubravčić; Mirjana Turkalj
Journal:  Am J Case Rep       Date:  2015-09-18

7.  ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T.

Authors:  Michele Menotta; Sara Biagiotti; Chiara Spapperi; Sara Orazi; Luigia Rossi; Luciana Chessa; Vincenzo Leuzzi; Daniela D'Agnano; Annarosa Soresina; Roberto Micheli; Mauro Magnani
Journal:  Orphanet J Rare Dis       Date:  2017-07-05       Impact factor: 4.123

8.  In vitro dexamethasone treatment does not induce alternative ATM transcripts in cells from Ataxia-Telangiectasia patients.

Authors:  Elisa Pozzi; Elisa Giorgio; Cecilia Mancini; Nicola Lo Buono; Stefania Augeri; Marta Ferrero; Eleonora Di Gregorio; Evelise Riberi; Maria Vinciguerra; Lorenzo Nanetti; Federico Tommaso Bianchi; Maria Paola Sassi; Vincenzo Costanzo; Caterina Mariotti; Ada Funaro; Simona Cavalieri; Alfredo Brusco
Journal:  Sci Rep       Date:  2020-11-19       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.